Tambaro, F. P., Singh, H., Jones, E., Rytting, M., Mahadeo, K. M., Thompson, P., … Wierda, W. G. (2021). Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia, 35(11), 3282–3286. https://doi.org/10.1038/s41375-021-01232-2

Tambaro, Francesco Paolo, Harjeet Singh, Emily Jones, Michael Rytting, Kris M. Mahadeo, Philip Thompson, Naval Daver, et al. “Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia.” Leukemia 35, no. 11 (November 2021): 3282–86. https://doi.org/10.1038/s41375-021-01232-2.

Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, et al. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia. 2021 Nov;35(11):3282–6.

Tambaro, Francesco Paolo, et al. “Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia.” Leukemia, vol. 35, no. 11, Nov. 2021, pp. 3282–86. Pubmed, doi:10.1038/s41375-021-01232-2.

Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, Daver N, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia. 2021 Nov;35(11):3282–3286.